Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01712074 : Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
PhasePhase 2
AgesMin: 60 Years Max: N/A
Eligibility
Inclusion Criteria:

- Clinical diagnosis of probable AD with supportive brain imaging documentation

- Have existing neuropsychiatric symptoms as defined by a score equal or greater than
10 on the NPI at screening, arising from item scores equal or greater than 2
(frequency X severity) on at least 2 domains.

- Has been on donepezil (stable dose of 5 mg or 10 mg) for at least four months, with
no intent to change such for the duration of the study.

Exclusion Criteria:

- Demonstrate extreme agitation, physical aggression or violence to themselves, their
caregiver, or others, and/or an inability to complete the ADAS-cog assessment at
Screening.

- Have major structural brain disease other than Alzheimer's Disease

- Other severe acute or chronical medical or psychiatric condition or laboratory
abnormality
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01712074      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740